Disclosure of positron emission tomography amyloid imaging results: A preliminary study of safety and tolerability.
INTRODUCTION: Three 18F-labeled radiopharmaceuticals have been Food and Drug Administration-approved for the identification of cortical amyloidosis in clinical settings. Although there has been strong debate among professionals as to the ethical and social consequences of disclosing […]
